As pharmaceutical manufacturers seek novel solutions for challenging conditions, cannabinoids—especially cannabidiol (CBD)—are emerging as promising candidates for drug innovation. With favorable regulatory developments and increasing scientific evidence supporting their potential in treating central nervous system disorders, pain, and cancer, cannabinoids are set to expand therapeutic possibilities. This whitepaper explores the latest research on cannabinoids and highlights how dsm-firmenich is partnering with the pharmaceutical industry to drive early-stage drug development in this exciting field. Download to learn more about advancing cannabinoid-based therapies.